Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours

BACKGROUND: Ewing sarcoma/PNET is managed with treatment paradigms involving combinations of chemotherapy, surgery, and sometimes radiation. Although the 5-year survival rate of non-metastatic disease approaches 70%, those cases that are metastatic and those that recur have 5-year survival rates of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelleher, Fergal C, Thomas, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351706/
https://www.ncbi.nlm.nih.gov/pubmed/22587874
http://dx.doi.org/10.1186/2045-3329-2-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351706/
https://www.ncbi.nlm.nih.gov/pubmed/22587874
http://dx.doi.org/10.1186/2045-3329-2-6

Ejemplares similares